With three decades of experience at MD Anderson, our Chief Information Officer Craig Owen oversees the operations of Information Services. He has been named one of the top chief information officers to know by Becker's Healthcare. Learn more: https://brnw.ch/21wKvjQ
MD Anderson Cancer Center
Hospitals and Health Care
Houston, TX 214,132 followers
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Our mission: #EndCancer
About us
The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. MD Anderson provides cancer care at several convenient locations throughout the Greater Houston Area and collaborates with community hospitals and health systems nationwide through MD Anderson Cancer Network®. U.S. News & World Report's "Best Hospitals" survey has ranked MD Anderson the nation's top hospital for cancer care. Every year since the survey began in 1990, MD Anderson has been named one of the top two cancer hospitals. The recognition reflects the passion of our 21,000 extraordinary employees and 1,000 volunteers for providing exceptional care to our patients and their families, and for realizing our mission to #EndCancer. You can view all of our career opportunities at careers.mdanderson.org.
- Website
-
http://MDAnderson.org
External link for MD Anderson Cancer Center
- Industry
- Hospitals and Health Care
- Company size
- 10,001+ employees
- Headquarters
- Houston, TX
- Type
- Educational
- Founded
- 1944
- Specialties
- Cancer, hospital, healthcare, oncology, research, doctor, health, wellness, medicine, education, education, science, health, clinical trials, nursing, cancer care, cancer research, training, fellowship, cancer education, cancer prevention, cancer treatment, and science and technology
Locations
Employees at MD Anderson Cancer Center
-
Guy Lipof
Data Science, AI, Executive, Healthcare & Life Sciences
-
Opral Wisham
QA Analyst V at Devon Energy
-
Ferran Prat Escude
Senior VP, Research Administration and Industry Relations at MD Anderson Cancer Center
-
Helio Dimas Nogueira
Executive Director - Project Management Officer, Technology & Innovation
Updates
-
MD Anderon’s James P. Allison Institute announces the appointment of its newest members, Drs. Susan Bullman and Xi Chen, to help advance impactful immunobiology research. Read about it here: https://brnw.ch/21wKtR7 #CancerResearch #EndCancer
Allison Institute announces appointment of two immunobiology experts as associate members
mdanderson.org
-
Our latest research advances include a lower-intensity treatment option for acute myeloid leukemia, a novel cell therapy for treating bone marrow failure, the use of MRI to analyze metabolic changes in tumors and presurgical targeted therapy for triple-negative breast cancer. Learn more. #CancerResearch #EndCancer
MD Anderson Research Highlights for June 5, 2024
mdanderson.org
-
Proton therapy achieves similar clinical outcomes and offers significant patient benefits when compared to traditional radiation therapy, according to results from a Phase III head and neck cancer clinical trial our Dr. Steven Frank will present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Read about the findings. #ASCO24 #CancerResearch #EndCancer
ASCO: Proton therapy demonstrates advantages in Phase III head and neck cancer trial
mdanderson.org
-
Our researchers are dedicated not only to finding new treatments for cancer but also to preventing it. Here are five ways MD Anderson researchers are studying the link between food and cancer. #CancerResearch #EndCancer
5 ways MD Anderson is researching the link between food and cancer
mdanderson.org
-
Today and every day, we celebrate the strength of cancer survivors, including those newly diagnosed with cancer, in active treatment, out of treatment and cancer caregivers. #NationalCancerSurvivorsDay #EndCancer
-
-
MD Anderson researchers share preliminary clinical data of an antibody drug conjugate for metastatic colorectal cancer and a USP1 inhibitor for advanced solid tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Learn about the findings from our Drs. Scott Kopetz and Timothy Yap. #ASCO24 #CancerResearch #EndCancer
ASCO: Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumors
mdanderson.org
-
Listen to our Dr. Tim Yap break down our latest Phase I research on DNA damage repair coming out of #ASCO2024: MDAnderson.org/Podcast #EndCancer
Cancerwise Podcast
mdanderson.org
-
Encouraging clinical data presented by Drs. Elias Jabbour and Alexandre Bazinet at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting offer new insights into improving treatments for relapsed or refractory B-cell acute lymphoblastic leukemia and acute myeloid leukemia. Read about their work here. #ASCO24 #CancerResearch #EndCancer
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
mdanderson.org
-
“As a leader in cancer care and research, we have the responsibility to harness AI’s potential to make an impact on quality of care, patient safety, research and streamlined operational processes,” says our Chief Data Officer Dr. Caroline Chung of how AI is used to advance our mission. “This is an exciting time and it’s only the beginning.” #CancerResearch #DataScience #EndCancer
3 things to know about AI and cancer care
mdanderson.org